Clinically meaningful HRQOL gains persisted to week 52 with mean changes of −1.66 (HEIS), −8.5 (DLQI), and +0.20 (EQ-5D-5L), ...

Recent results from the TETON-1 phase 3 clinical trial assessing inhaled treprostinil to treat idiopathic pulmonary fibrosis ...

New findings from the SPIRIT-HF (NCT04727073) trial are helping to refine the clinical role of spironolactone (Aldactone; ...

Outcome-weighted metrics (mortality, 5-year survival, MIR) better capture unmet need than incidence alone when assessing ...

Experts from AMCP emphasize the importance of drug-adjacent early detection tests and screening ability to improve patient ...

Experts from AMCP discuss the real-world evidence on GLP-1 usage and health care spending. In this Q&A, Urick discusses the ...

LaShawn McIver, MD, MPH, discusses a new report from a task force aiming to cut chronic disease prevalence 10% by 2035 ...

LaShawn McIver, MD, MPH, discusses a new report from a task force aiming to cut chronic disease prevalence 10% by 2035 ...

Daryl Pritchard, PhD, discusses the challenges to implementing biomarker testing that would advance precision medicine and ...

At AMCP 2026, Kelsea Aragon, PharmD, discussed PrEP coverage, long-acting injectables, and payer strategies to improve HIV ...

Genomic profiling enables therapy individualization when actionable mutations (FLT3, NPM1, IDH1/2, TP53) are present, moving ...

Quality metrics for screening tests must evolve to mandate diagnostic resolution, ensuring financial and clinical incentives ...